Testosterone is the primary male sex hormone, produced mainly in the testes and regulated by the hypothalamic-pituitary-gonadal (HPG) axis. It peaks in early adulthood and naturally declines at approximately 1–2% per year after the age of 30.
Testosterone is the primary male sex hormone, produced mainly in the testes and regulated by the hypothalamic-pituitary-gonadal (HPG) axis. It peaks in early adulthood and naturally declines at approximately 1–2% per year after the age of 30.
This gradual decline is normal. The clinical condition — variously called hypogonadism, androgen deficiency, or late-onset hypogonadism — occurs when levels fall low enough to produce symptoms that meaningfully affect quality of life.
A landmark European study (the EMAS study, Wu et al., NEJM 2010) identified that late-onset hypogonadism affects approximately 2.1% of men aged 40–79, though subclinical low testosterone is considerably more common. In Singapore, with a large middle-aged male population and high rates of metabolic risk factors (obesity, type 2 diabetes, sleep apnoea) — all of which suppress testosterone — the prevalence is likely substantial.
The symptoms of low testosterone are non-specific, which is why many men don't immediately connect them to a hormonal cause. Common signs include:
Physical symptoms:
- Persistent fatigue and low energy, even with adequate sleep
- Reduced muscle mass and increased body fat, particularly around the abdomen
- Decreased bone density (may present as fractures or back pain in later stages)
- Reduced body and facial hair
- Hot flushes or night sweats (less common, but documented)
Sexual symptoms:
- Reduced libido (sex drive)
- Erectile dysfunction
- Reduced ejaculatory volume
- Infertility (in some cases)
Cognitive and psychological symptoms:
- Low mood, irritability, or depressive symptoms
- Difficulty concentrating or mental "fogginess"
- Reduced motivation and drive
It's important to note that these symptoms can have multiple causes. Low testosterone is a diagnosis of exclusion — other conditions must be ruled out, and the symptoms must correlate with a confirmed low blood testosterone level before treatment is considered appropriate.
Diagnosis requires a combination of clinical assessment and laboratory testing. No single symptom is sufficient — diagnosis requires both symptoms and confirmed low serum testosterone.
A validated questionnaire such as the Androgen Deficiency in the Aging Male (ADAM) questionnaire or the Aging Males' Symptoms (AMS) scale is often used to systematically assess symptoms before lab testing.
Testosterone levels should be measured via a morning fasting blood draw, typically between 7am and 10am, when levels are at their daily peak. Tests include:
Most guidelines recommend two separate low readings taken on different days before a diagnosis of hypogonadism is confirmed. The commonly accepted threshold is a total testosterone below 300 ng/dL (10.4 nmol/L), though clinical judgement applies — some men are symptomatic at higher levels, particularly if SHBG is elevated.
In Singapore, these tests are available through polyclinics, private GPs, and specialist clinics (urologists, endocrinologists). Increasingly, they are also accessible through licensed telehealth platforms that can arrange home blood draws and remote consultations.
TRT is a prescription medical treatment that restores testosterone levels to within the normal physiological range. It is not a performance enhancer or supplement — it is a clinically supervised intervention for men with confirmed hypogonadism.
The goal of TRT is not supraphysiological levels. It is symptom relief within the normal range.
Several delivery methods exist, each with different dosing schedules, absorption profiles, and practical considerations:
Intramuscular injections
The most common form globally. Testosterone cypionate or enanthate is injected every 1–2 weeks; longer-acting undecanoate formulations (e.g. Nebido) allow injections every 10–14 weeks. Injections produce reliable serum levels and are generally the most cost-effective option.
Topical gels and creams
Applied daily to the skin (typically shoulders or upper arms). Convenient for men who dislike injections, but require care to avoid skin-to-skin transfer to partners or children. Levels are stable but daily compliance is essential.
Transdermal patches
Applied to the skin daily. Less commonly used than gels due to higher rates of skin irritation.
Testosterone pellets (subcutaneous implants)
Small pellets inserted under the skin every 3–6 months by a clinician. Uncommon in Singapore but available in some specialist settings.
The choice of formulation depends on patient preference, clinical factors, and cost. A licensed doctor will advise on the most appropriate option.
TRT is one of the more extensively studied hormone therapies. The Testosterone Trials (TTrials) — a coordinated group of seven clinical trials published in high-impact journals — represent the most rigorous recent evidence base.
Key findings relevant to men considering TRT:
The evidence supports TRT for improving sexual symptoms, mood, energy, and body composition in men with confirmed hypogonadism. Effects on cardiovascular outcomes remain an area of active research; current guidelines do not recommend TRT in men with recent cardiovascular events.
TRT is not appropriate for all men. Contraindications include:
Baseline PSA testing, haematocrit measurement, and cardiac risk assessment are standard before initiating TRT.
Once treatment is started, regular follow-up is essential. Standard monitoring includes:
A well-managed TRT programme is not a one-time prescription — it requires ongoing clinical oversight.
TRT is a prescription treatment in Singapore and must be initiated and supervised by a licensed medical practitioner. It is not available over the counter or through unregulated supplement channels.
Options for assessment include:
- GP clinics with an interest in men's health
- Urology or endocrinology specialists (typically via GP referral)
- Licensed telehealth platforms offering remote consultations with qualified doctors, home blood draw arrangements, and prescription delivery
Noah is a prescription telehealth platform supporting men's health in Singapore. If you're experiencing symptoms consistent with low testosterone, you can speak with a licensed doctor online — no referral required, no waiting room.
[Speak with a Noah doctor about low testosterone → ofnoah.sg]
Q: Can I test my testosterone at home?
A: Home finger-prick tests exist but are not clinically validated for diagnosing hypogonadism. A proper diagnosis requires a venous blood draw, ideally taken in the morning, with results interpreted in the context of symptoms by a qualified doctor.
Q: Is TRT the same as anabolic steroids?
A: No. TRT uses pharmaceutical-grade testosterone at doses designed to restore normal physiological levels. Anabolic steroid misuse involves supraphysiological doses (far above normal range) for performance enhancement — a very different context with significantly higher risk profiles.
Q: Will TRT affect my fertility?
A: TRT suppresses the body's own testosterone production via the HPG axis, which reduces sperm production. Men who want biological children should discuss fertility-preserving alternatives with their doctor before starting TRT.
Q: How long before I feel results from TRT?
A: Effects vary by symptom. Libido improvements may be noticed within 3–6 weeks; mood and energy changes typically within 3 months; body composition changes (muscle gain, fat loss) take 3–6 months or more. Bone density changes take 1–2 years. Consistent monitoring is essential.
Q: Is TRT available through Singapore's national health system?
A: TRT is available through public hospitals and specialist clinics, typically via GP referral. Private and telehealth options offer faster access without a referral requirement.
This article is for educational purposes only and does not constitute medical advice. Testosterone replacement therapy is a prescription treatment and should only be initiated following assessment by a licensed medical professional.
References: Wu FCW et al. NEJM 2010; Bhasin S et al. NEJM 2018; Snyder PJ et al. JAMA 2018; Resnick SM et al. NEJM 2017. AUA Guidelines on Testosterone Deficiency 2022.

